Neuren Pharma ( NEU.AX ) has probably more potential than any biotech on the asx. Their products & technologies are pretty sound.
Please do your own dd...
Neuren Pharmaceuticals Announces Glypromate Trial Recruits 100th Patient Thursday January 17, 2008, 9:32 am
Original Announcement: Glypromate trial recruits 100th patient
Neuren Pharmaceuticals announced that its Phase III clinical trial with lead compound Glypromate, in development to reduce cognitive impairment following cardiac surgery, has recruited its 100th patient. This is in line with the trial's objective of completing enrolment by December 2008, as almost all sites are now recruiting. The Data Safety Monitoring Committee will review the patient data of these 100 patients and again at 300 patients in mid-2008.
Neuren Pharma ( NEU.AX) Marketcap: only 23 million A$ Price: 0,16 A$
News http://au.finance.yahoo.com/q/aca?s=NEU.AX
Awesome Pipeline :
Glypromate MCI in CABG Phase III ongoing NNZ-2566 Severe TBI(traumatic brain injury)Phase IIa NNZ-2566 Mild/Mod TBI Phase II Motiva Post-stroke-Apathy Phase IIb
Clinical development update 4 Dec 2007: http://www.neurenpharma.com/images/NEU%20Clinical%20Trials%20Update%20Dec%202007.pdf
Presentation 3 Dec 2007: http://www.neurenpharma.com/images/Neuren%20AU%20Presentation%20Dec%202007.pdf
Homepage: http://www.neurenpharma.com/
Taylor Collison http://preset.sphilo.com/neuren/images/NEU%200708%20-%20Hamilton.pdf
By the end 1Q CY08, we expect Neuren to be running four major efficacy trials; namely three Phase 2 trials for NNZ-2566 in mild/moderate and severe TBI and Motiva� in post stroke abulia/ depression coupled with the current Phase 3 trial for Glypromate� in CABG. All indications potentially provide Neuren with first to market, billion dollar opportunities. With a current market cap of $40.2m, Neuren remains a solid value proposition in the sector, where FDA INDs for mid to late stage clinical trials continues to remain a vexing proposition. We maintain our Speculative Buy recommendation and price target of $1.30, though expect to make changes to our valuation model once the acquisition has closed, which we expect during the current Q.
BLT Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held